The European Commission accepted legally binding commitments from pharmaceutical company Sanofi following competition concerns involving promotional communications about a rival influenza vaccine.
The investigation examined whether communications concerning CSL Seqirus's Fluad vaccine could have misled healthcare professionals in Germany and France and distorted competition with Sanofi's Efluelda vaccine.
The commitments require corrective measures and restrictions on similar communications. The Commission's decision resolves the identified concerns without a formal finding that EU competition law was infringed.
The case highlights the importance of accurate information in pharmaceutical markets, where clinicians and patients rely on scientific evidence and public health recommendations when choosing preventive care.
